Novartis Oncology

About

Novartis Oncology, a division of Novartis, leverages science‑based innovation to discover, develop, and deliver breakthrough cancer therapies. The unit’s portfolio addresses more than 25 oncology indications across five key areas—breast, lung, melanoma, kidney, and hematologic cancers—and currently has around 30 investigational compounds in development. Committed to expanding patient access worldwide, Novartis Oncology integrates cutting‑edge research, immuno‑oncology, and rigorous quality standards to bring new treatments to market, offering a dynamic environment for professionals dedicated to advancing oncology care.